Citation Impact
Citing Papers
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
2013 Standout
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
Diabetes and Cardiovascular Disease
1999 Standout
FRAX™ and the assessment of fracture probability in men and women from the UK
2008 Standout
Abdominal obesity and metabolic syndrome
2006 StandoutNature
Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death
2006 Standout
Diagnosis of osteoporosis and assessment of fracture risk
2002 Standout
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2003 Standout
Functional consequences of angiotensin-converting enzyme gene polymorphism on N-acetyl-Ser-Asp-Lys-Pro degradation and angiotensin II production
2002
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
2005 Standout
A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO)
2006
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
2004 Standout
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
2002 Standout
Intervention thresholds for osteoporosis
2002
Role of the N-terminal Catalytic Domain of Angiotensin-converting Enzyme Investigated by Targeted Inactivation in Mice
2004 StandoutNobel
Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond
2007 Standout
An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas
2003
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
2010 Standout
Role of Oxidative Modifications in Atherosclerosis
2004 Standout
The development of allergic inflammation
2008 StandoutNature
Fish Intake, Contaminants, and Human Health
2006 Standout
Effect of the Insertion/Deletion Polymorphism of the Angiotensin-Converting Enzyme Gene on Response to Angiotensin-Converting Enzyme Inhibitors in Patients with Heart Failure
1998
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
2003 Standout
Updated Risk Factor Values and the Ability of the Multivariable Risk Score to Predict Coronary Heart Disease
2004
Cardiorespiratory Fitness as a Quantitative Predictor of All-Cause Mortality and Cardiovascular Events in Healthy Men and Women
2009 Standout
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
2007 Standout
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis
2004 Standout
Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups
2008 Standout
Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial???Lipid Lowering Arm (ASCOT-LLA)
2004
Validation of the Framingham Coronary Heart Disease Prediction Scores
2001 Standout
Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical Outcomes
2006 Standout
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
2005 Standout
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease
2003 Standout
Pathophysiology of Human Visceral Obesity: An Update
2013 Standout
Definition of Metabolic Syndrome
2004 Standout
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus
2005 Standout
AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update
2006 Standout
Prediction of Coronary Heart Disease Using Risk Factor Categories
1998 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Clinical significance of the sparteine/debrisoquine oxidation polymorphism
1989
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
2013 Standout
Principles for National and Regional Guidelines on Cardiovascular Disease Prevention
2004
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
2001
Statins for the primary prevention of cardiovascular disease
2013
Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation
2007 Standout
Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
2008 Standout
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths
2007 Standout
n–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
2013 Standout
Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction
2007 Standout
Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis
2016 Standout
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
2003 Standout
How general practitioners perceive and grade the cardiovascular risk of their patients
2004
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
1999 StandoutScience
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
2012 Standout
General Cardiovascular Risk Profile for Use in Primary Care
2008 Standout
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
2004 Standout
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
2006 Standout
Pathophysiology and clinical presentations of cough
1996
Preventives Versus Treatments *
2015 StandoutNobel
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
2005 Standout
beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination.
1991
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Works of PR Jackson being referenced
Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table
1996
Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.
1986
Effect of dose adjustment on enalapril‐induced cough and the response to inhaled capsaicin.
1995
A New Regimen for Starting Warfarin Therapy in Out-Patients
1997
Quantification of side‐effects of beta‐adrenoceptor blockers using visual analogue scales.
1984
Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects.
1995
Side‐effects of beta‐adrenoceptor blocking drugs assessed by visual analogue scales.
1985
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
1984